AbbVie/InterMune must show 'irreparable' harm from data disclosure, says top EU court
This article was originally published in SRA
Executive Summary
Efforts by AbbVie and InterMune to prevent the European Medicines Agency from disclosing clinical trial data on their products Humira and Esbriet have hit a hurdle after the EU's highest court set aside the interim measures granted to the companies by the General Court earlier this year1-3.
You may also be interested in...
Australia To Give Consumers More Formal Role In HTA Processes
The health department says consumers and patients should be able to initiate health technology assessments because many potentially helpful and lifesaving medicines might never be assessed for funding due to “a lack of commercial incentive for pharmaceutical companies.”
EC Defends Data Protection Cut As EU ‘Pharma Package’ Nears Crucial Milestone
Proposals to overhaul the general pharmaceutical legislation will ensure that the EU “continues to have one of the most generous systems of incentives in the world,” the European Commission says.
European Parliament Clears EU-Wide Compulsory Licensing Proposal
The draft regulation, which includes a ban on exports of drugs manufactured under an EU compulsory license, will be discussed with the EU member states after the June parliamentary elections.